564 DOI: 10.17344/acsi.2016.2970
Acta Chim. Slov. 2017, 64, 564-570
Scientific paper
Use of Differential Scanning Calorimetry and Immunoaffinity Chromatography to Identify Disease Induced Changes in Human Blood Plasma Proteome
Sandi Brudar,1 Urh Cernigoj,2 Helena Podgornik,3 Mojca Krzan4
and Iztok Prislan5*
1 University of Ljubljana, Faculty of Chemistry and Chemical Technology, 1000 Ljubljana, Slovenia 2 BIA Separations, 5270 Ajdov{~ina, Slovenia 3 University Medical Centre Ljubljana, Department of Haematology, 1000 Ljubljana, Slovenia
4	University of Ljubljana, Faculty of Medicine, 1000 Ljubljana, Slovenia
5	University of Ljubljana, Biotechnical Faculty, 1000 Ljubljana, Slovenia
* Corresponding author: E-mail: iztok.prislan@bf.uni-lj.si
Received: 05-10-2016 For Cutting Edge 2017
Abstract
Differential scanning calorimetry provides unique signatures of blood plasma samples. Plasma samples from diseased individuals yield specific thermograms, which differ from each other and from plasma samples of healthy individuals. Thermograms from individuals suffering from chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia were measured with DSC. To obtain additional information about thermal behaviour of plasma proteins immunoaffinity chromatography was introduced. An immunoextraction of HSA using a chromatographic column with immobilized anti-HSA was carried out in order to enrich less abundant plasma proteins, which could provide a further insight into disease development. Efficiency of HSA depletion and protein composition of fractionated plasma was validated by SDS-PAGE.
Keywords: DSC, IAC, blood plasma, immunoextraction, diagnostic tool
1. Introduction
Despite of rapid development of medicine and other sciences, timely and reliable diagnosis of diseases is sometimes still a pretentious task. In addition when it comes to ascertaining the health status of an individual some diagnostic procedures are very invasive. A solution to such difficulties could lie in new methods for human plasma analysis. Human plasma serves as an important source of information about human health. Various diseases are often associated with biomarkers, which have been defined by Hulka et al. as biochemical, molecular or cellular changes that are measureable in human fluids, tissues and cells.1 The human plasma proteome consists of more than
3000 proteins and peptides, therefore the search for potential disease biomarkers, and their identification in the plasma proteome is a very complicated procedure.2 Only ten proteins make up 90% of the mass of plasma proteins and albumin (HSA) and immunoglobulins (Ig) represent 75% out of these ten proteins. Majority of biomarkers in blood plasma are often scarce and small in size. Consequently, their detection can be limited by the presence of more abundant and larger proteins such as HSA or IgG2. Because of the complexity of plasma no single technique can fully exploit the information plasma has to offer. Until now mass spectrometry and 2D-electrophoresis have been routinely used for detection and characterization of specific biomarkers.3 Chaires et al. have discovered the poten-
tial use of differential scanning calorimetry (DSC) for plasma analysis.2 Using a DSC to analyze plasma yields a thermogram that is sensitive to differences in thermodynamic properties of the most abundant plasma proteins. Chaires et al. have shown that thermograms of plasma from diseased individuals differ significantly from ther-mograms of plasma from healthy individuals.2'4 Another tool to facilitate the search for biomarkers is liquid chro-matography' in particular affinity chromatography and ion-exchange chromatography. Several researchers have demonstrated that depletion of most abundant plasma proteins amplifies the contribution of least abundant plasma proteins' thus creating the opportunity to uncover and study specific proteins/peptides.56 Polymethacrylate chromatographic monoliths afford flow rate independent binding capacity and resolution for large biomolecules due to the convective nature of the flow, which allows relatively short analysis times compared to traditional chro-matographic supports.7 Having these advantages in mind we decided to partially deplete human serum albumin from plasma sample using chromatographic monoliths bearing immunoaffinity ligand. The purpose of our research was to develop and optimize procedures for combined use of DSC and immunoaffinity chromatography (IAC) for the investigation of different plasma samples from diseased individuals.
2. Experimental
2. 1. Plasma Samples
We investigated plasma samples from three individuals with three different haematological diseases' namely chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML). Individuals diagnosed with MM and AML were females and the one with CLL was a male. Due to ethical issues further information about these individuals cannot be revealed. Chaires et al.8 have shown that the main shape of plasma thermograms is unbiased by age, gender and ethnicity, however small deviations in HSA unfolding signal amplitudes can be observed due to higher HSA concentrations in male plasma samples. For the control sample blood plasma from a healthy child was used. At the University Medical Centre Ljubljana (UMCL) the peripheral blood samples were withdrawn in tubes with EDTA and centrifuged at 2500 RPM for 10 minutes to obtain plasma. The use of plasma was approved by National Medical Ethics Committee (Approval number: MZ 0120-299/2016-2, KME 83/05/16)
Because only 3 plasma samples were investigated we have to emphasize that this is only a preliminary study in which our main aim was to identify the effectiveness of our approach and not to generalize differences for the three investigated diseases. It should be clear that for validation of our method more plasma samples should be
analyzed. Even though only one set of measurements was performed for CLL and AML samples, the robustness and reproducibility of our method was tested with other plasma samples (data not shown) and two separate fractiona-tions of MM sample (Figure S1).
2. 2. Sample Preparation
The buffer solutions used in our experiments consisted of 20 mM disodium phosphate and 300 mM NaCl. HCl was added to disodium phosphate to reach pH of 7.4. All buffers were filtered before use. Samples were first diluted 5- to 7-fold and then extensively dialyzed against the buffer at 4 °C (three changes of buffer solution in 24 h) using a dialysis tube Float-A-Lyzer with a 3500 Da cut-off. Total protein concentration of plasma samples was determined spectrophotometrically according to the bicincho-ninic acid method procedure (Sigma-Aldrich).9
2. 3. IAC Protocol
Separations were performed using a Knauer highperformance liquid chromatography (HPLC) workstation, consisting of two pumps, an autosampler injection system with a sample loop volume of 100 pL and a UV-detector at a wavelength of 280 nm. Samples were loaded by using a mobile phase consisting of 20 mM disodium phosphate and 300 mM NaCl, pH = 7.4 at a flow rate of 1 mL/min. For experimental data acquisition, Eurochrom 2000 software was used. The hydrazide-modified monolithic chromatographic column (CIM® HIDA) with 1 mL bed volume and 6 pm pore size was provided by BIA Separations d.o.o. The immobilization of polyclonal anti-HSA was performed according to the procedure described by Tarasova et al.10 and the determined dynamic binding capacity at 50% breakthrough of prepared CIM aHSA column for pure HSA in phosphate buffered saline was 0.35 mg/mL. Before injection, diluted and dialyzed plasma samples were filtered through 0.45 pm membrane filters (Sartorius) and diluted with dialysate to a total protein concentration of approximately 4 to 5 mg/mL. 100 pl loop was used to load the sample and flow-through and bound fractions of plasma were collected. Succeeding collection of flow-through fraction the bound fraction was eluted using 0.1 M HCOOH, pH = 2.5, followed by immediate neutralization by 200 mM disodium phosphate, 300 mM NaCl, pH = 8.5. Both fractions were transferred to Vivaspin sample concentrators with MWCO of 3500 Da and centrifuged to final volume of 1 to 1.5 mL at 5000 RPM. This was repeated 18 times.
2. 4. DSC Protocol
DSC thermograms were obtained using nano DSC II (CSC). Dialyzed plasma samples were diluted 3- to 4-fold with dialysate and degassed for 15 min. DSC scans were
recorded from 20 °C to 100 °C at 2 °C/min. Corresponding buffer scans were also recorded. Raw data was analyzed with NanoAnalyze software and Microsoft Excel. The corresponding baseline (buffer-buffer) scans were subtracted from the plasma scans and normalized to total protein concentration to obtain partial heat capacity as a function of temperature.
2.	5. SDS-PAGE
Fractions were examined using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Plasma fractions from IAC were diluted to a final concentration between 0.5 and 1.0 mg/mL. Separation of proteins was performed on 12% resolving gel and 4% stacking gel. Electrophoresis was carried out under reducing conditions according to the basic Laemmli SDS-PAGE procedure.11 Gels were run at 200 V and 15 °C for 75 min. Visualization of protein bands was done by silver staining.12 Gel images were altered to achieve more efficient interpretation of result (color was changed to black&whi-te and positions of lanes on the same gel were shuffled). Unaltered images can be seen in Figure S2.
3. Results and Discussion
3.	1. Comparison of Blood Plasma
Thermograms
Figure 1 shows that plasma thermograms belonging to diseased individuals differ significantly from one another and from "healthy" plasma thermograms. The thermo-
50 60 70 BO 90 100 77° C
Figure 1. Comparison of thermograms of blood plasma from diseased individuals dissolved in 20 mM phosphate buffer and 300 mM NaCl and with a thermogram of blood plasma from healthy individual dissolved in 10 mM phosphate buffer and 150 mM NaCl (dashed cyan line) and 20 mM phosphate buffer and 300 mM NaCl (full cyan line).
grams of plasma display multiple peaks that can be associated to the melting temperatures (Tm) characteristic of main plasma proteins.
Chaires et al. have performed thermal denaturation of "healthy" blood plasma at heating rate of 1 °C/min and in 10 mM phosphate buffer with 150 mM NaCl to mimic physiological conditions. Several peaks were identified corresponding to transition temperatures of fibrinogen (Tm~51 °C), HSA (Tm~63 °C), IgG (Tm~70 °C) and transferrin (Tm~85 °C).2 Thermograms in our research were recorded at heating rate of 2 °C/min to increase the number of processed samples and 20 mM phosphate buffer with 300 mM NaCl was used to avoid non-specific plasma-column interactions. Higher heating rate and salt concentration shifted the melting temperatures of majority of plasma proteins to higher values (Figure 1). Thus Tm of fibrinogen shifts to ~53 °C, Tm of HSA to ~67 °C, Tm of IgG to ~72 °C) and Tm of transferrin to ~86 °C. Melting temperatures are not the only obtainable data from thermograms. The integration of area under the thermograms of plasma yields the enthalpy of plasma proteins denaturation (Table 1).
Table 1. Denaturation enthalpies of plasma from healthy individual and from blood plasma of diseased individuals. NF-non-fractio-nated plasma; F1-flow-through plasma fraction. Experimental error due to baseline correction is ± 5%.13
Sample	Unfolding enthalpy [cal/g]
Healthy plasma	3.64 ± 0.18
CLL plasma NF	3.80 ± 0.19
CLL plasma F1	2.94 ± 0.15
AML plasma NF	3.96 ± 0.20
AML plasma F1	2.89 ± 0.14
MM plasma NF	4.57 ± 0.23
MM plasma F1	4.27 ± 0.21
Figure 1 shows that thermograms obtained from thermal denaturation of blood plasma from diseased individuals are shifted to higher temperatures. The shift in unfolding temperatures is in agreement with previously reported results for other diseases.2'14'15'16 Proteins in plasma from diseased individuals seem to unfold at higher temperatures for a yet undefined reason. Chaires et al. had hypothesized that such stabilization of proteins occurs due to interactions between major plasma proteins and specific disease biomarkers.2 Thermal denaturation of plasma from an individual with CLL yields a thermogram' where at least four transitions could be identified. These could correspond to denaturation of fibrinogen (Tm~53 °C), HSA (Tm~68 °C), IgG (Tm~72 °C) and transferrin (Tm~91 °C). The transitions are shifted from 0 to 5 °C towards higher temperatures when compared to thermogram of "healthy" plasma. For instance' Tm of fibrinogen does not change, but Tm of transferrin is shifted for approximately
5 °C. The denaturation enthalpy of non-fractionated CLL plasma is 3.80 ± 0.19 cal/g. This value is approximately the same as the denaturation enthalpy of plasma proteins from healthy individuals. Figure 1 shows that DSC thermograms of CLL and AML plasma are distinct even though both diseases are characterized by prominent changes in blood leukocytes not in plasma protein composition. In the thermogram of plasma from an individual with AML an additional endothermic peak can be observed at 62 °C. We hypothesize this peak is present due to thermal denaturation of haptoglobin, as it is supposed to
unfold in the same temperature region as HS A.- Tm values	o,o -I—i
of fibrinogen and transferrin from AML plasma denaturation seem to be at approximately the same position as Tm values from "healthy" plasma denaturation. The denaturation enthalpy of non-fractionated blood plasma from an individual with AML is 3.96 ± 0.20 cal/g, which is comparable to denaturation enthalpy of CLL and "healthy" plasma. Lastly Figure 1 shows a specific thermogram of plasma from an individual with MM. Three main transition peaks for most abundant plasma proteins can be characterized. A similar thermogram for this disease was obtained by Todinova et al.17 Thermally induced peaks are shifted to higher temperatures to an even greater extent than those characteristic for proteins from CLL and AML plasma samples. Also in contrast to AML and CLL samples protein concentration in MM plasma was increased above reference range (94 g/L) due to monoclonal IgG fraction (M spike) typical for MM. Thermogram exhibits three distinct peaks (Tm1~62 °C, Tm2~71 °C and Tm3~82 °C) and is dramatically different from other thermograms. The determined enthalpy of denaturation for non-fractionated MM plasma was 4.57 ± 0.23 cal/g, which is approximately 20% higher from denaturation enthalpies of other samples. These results suggest that the amount of unfolding enthalpy is not a determining factor for disease conditions. We believe that only the shape of plasma ther-mograms can serve as a diagnostic tool for disease determination.
3. 2. Fractionation and Characterization of Proteins in Blood Plasma
To gain further insight into thermal behavior of different blood plasma samples, fractionation of plasma samples and thermal denaturation of obtained fractions were carried out. The thermogram of the flow-through fraction of plasma from an individual with CLL in Figure 2 shows a distinct drop in signal intensity in the region characteristic of HSA, as a result of HSA depletion by a CIM aHSA column. As a result, transition peaks for other proteins are more pronounced. Along with enrichment of less abundant proteins we can observe an entirely new peak at approximately 65 °C, which seems to have been previously masked by HSA. We hypothesize that this peak is a result of haptoglobin denaturation.
Figure 2. Thermograms of blood plasma from an individual with CLL (top). DSC thermogram of a non-fractionated blood plasma sample (full line) is compared to thermograms of flow-through (dotted line) and bound fraction (dashed line) obtained from HPLC fractionation. The right AC^ axis corresponds to the bound fraction. SDS-PAGE of blood plasma from an individual with CLL (bottom); P. L. - protein library, CLLNF - non-fractionated blood plasma (1 mg/mL), CLLF1 - flow-through fraction (1 mg/mL), CLLF2 - bound fraction (0.8 mg/mL).
The obtained unfolding enthalpy of the flow-through fraction of CLL plasma was 2.94 ± 0.15 cal/g (Table 1), which is 22% lower than that of non-fractionated plasma. The thermogram of the bound fraction in Figure 2 shows a major exothermic effect above 82 °C due to protein aggregation. We hypothesize that this phenomenon is due to elution of HSA with HCOOH, even though this fraction was intercepted by high capacity buffer to neutralize acid. Very acidic conditions are non-physiological for HSA and can change its structure in a way that favors aggregation. Similar behavior of bound fractions was observed in all plasma samples and reported by other researchers18,19 and will not be discussed any further. Together with the thermogram of the flow-
through fraction, results of SDS-PAGE (Figure 2) show that only partial HSA depletion was achieved even though the applied concentration was bellow theoretical binding capacity. This was most likely due to complexity of plasma samples and overuse of our CIM aHSA column. Even though HSA is still present in the flow-through fraction, the corresponding thermogram seems to be missing peak assigned to HSA denaturation. We have to assume that HSA unfolding is masked by the unfolding of other plasma proteins. CLLF2 lane (bound fraction) displays an intensive band at 66 kDa, characteristic of HSA, no slower migrating bands and some low intensity bands in lower MW region that could correspond to heavy (~50 kDa) and light (~25 kDa) IgG chains. Results of flow-through fraction PAGE can be seen in CLLF1 la-
ne. An intensive band at ~180 kDa, representing a subunit of a2-macroglobulin, is present in the high MW y-region. Below in the P-region lies a distinct band at 80 kDa, characteristic of transferrin. HSA band is less intensive but still present because in order to reduce the number of fractionations, high concentration of plasma with HSA concentration on the limit of binding capacity was injected on CIM aHSA column. Beneath the band representing HSA there is a broader band consisting of BP-fibri-nogen at ~56 kDa, transthyretin at ~55 kDa and heavy Ig-G chains at ~50 kDa. The band at ~15 kDa could not be identified.20 It is clear that intensities of all bands, which were weaker in the whole plasma sample are noticeably increased in the CLLF1 lane, suggesting that enrichment of less abundant proteins was successful.
Figure 3. Thermograms of blood plasma from an individual with AML (top). DSC thermogram of a non-fractionated blood plasma sample (full line) is compared to thermograms of flow-through (dotted line) and bound fraction (dashed line) obtained from HPLC fractionation. The right AC^ axis corresponds to the bound fraction. SDS-PAGE of blood plasma from an individual with AML (bottom); P. L. - protein library, AMLNF - non-fractionated blood plasma (1 mg/mL), AMLF1 - flow-through fraction (1 mg/mL), AMLF2 - bound fraction (0.7 mg/mL).
Figure 4. Thermograms of blood plasma from an individual with MM (top). DSC thermogram of a non-fractionated blood plasma sample (full line) is compared to thermograms of flow-through (dotted line) and bound fraction (dashed line) obtained from HPLC fractionation. The right ACp axis corresponds to the bound fraction. SDS-PAGE of blood plasma from an individual with MM (bottom); P. L. - protein library, MMNF - non-fractionated blood plasma (1 mg/mL), MMF1 - flow-through fraction (1 mg/mL), MMF2 -bound fraction (0.5 mg/mL).
The thermogram of the flow-through fraction of AML plasma (Figure 3) shows that depletion of HSA from blood plasma resulted in well-defined peak at 62 °C which in our opinion is a result of haptoglobin denatura-tion. Signals for other plasma proteins, such as fibrinogen at 53 °C and transferrin at 86 °C are also slightly enriched. The remaining peak at 72 °C can be attributed to IgG de-naturation. The obtained unfolding enthalpy for the flow-through fraction was 2.89 ± 0.14 cal/g (Table 1), which is approximately 27% lower than for non-fractionated AML plasma. Thermogram obtained from thermal denaturation of the bound fraction of AML plasma (Figure 3) displays an intensive endothermic peak, followed by a steep exothermic effect characteristic of protein aggregation. Results of SDS-PAGE of AML plasma (Figure 3) show an intensive HSA band in AMLF2 lane, suggesting that we have successfully depleted the majority of HSA from the AML plasma. Some faster migrating bands corresponding to heavy (~50 kDa) and light (~25 kDa) IgG chains can also be seen in AMLF2 lane. AMLF1 lane corresponds to the flow-through fraction and contains a band at 66 kDa showing that not all of HSA was removed. The intensities of other bands are increased, proving that we have succeeded in increasing the relative concentration of other proteins.
When comparing thermograms of non-fractionated sample and flow-through fraction of the MM plasma (Figure 4), a distinct drop in signal intensity at temperature of 71 °C and increase in signal intensity at temperature of 82 °C are observed. The denaturation enthalpy of the flow-through fraction was 4.27 ± 0.21 cal/g, which is only 7% lower than for non-fractionated MM plasma. SDS-PAGE of MM flow-through fraction, MMF1, shows decreased intensity of HSA band at 66 kDa and increased intensities of other bands (Figure 4). On the other hand SDS-PAGE of MM bound fraction, MMF2, shows strong band, characteristic of HSA along with weaker bands representing heavy and light IgG chains. SDS-PAGE results suggest that almost all of the HSA is removed from flow through fraction which could be associated to drop in DSC signal intensity at temperature of 71 °C. Thermograms of MM plasma show that HSA and IgG unfolding have shifted to higher temperature, perhaps due to interactions with drugs21 or interactions with monoclonal immu-noglobulin.22 About 25 % drop in DSC signal intensity at temperature of 71 °C does not correspond to drop in band intensity observed in SDS-PAGE which means that HSA is unfolding in the same region as other proteins. Comparison of lanes with bound fractions in Figures 2, 3 and 4 reveals that the intensities faster migrating bands are strongest in the case of MM plasma. This could be a result of HSA-IgG complex formation, non-specific interactions or column degradation and should be further investigated. The stained gel (Figure 4) gives information not only about the effectiveness of MM plasma fractionation, but also of multiple myeloma signs. This is especially evident
from several protein bands in MMNF lane. A weak band, characteristic of HSA and abnormally intensive bands, characteristic of heavy and light IgG chains can be observed. Both phenomena are typical of multiple myeloma20 and it should be emphasized that MM plasma was obtained from patient with IgG clonality and light chain kappa restriction.
4. Conclusions
DSC provides a unique signature of the three examined diseases (chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia), thus showing potential for plasma proteome investigation. Because only 3 plasma samples were investigated we have to emphasize that obtained results may not be used to generalize differences for the three investigated diseases. IAC with the use of a CIM aHSA column enables enrichment of less abundant plasma proteins, thus providing the tool to enhance the relative presence and/or influence of potential disease biomarkers. Enrichment of plasma proteins in flow-through fractions was verified with SDS-PAGE and analyzed with DSC. The obtained results suggest that combination of DSC and IAC could be introduced as a possible novel and non-invasive diagnostic tool, although further research in this field is required.
5. Acknowledgements
We acknowledge the financial support of the Slovenian Research Agency through Program Groups P1-0201, P4-0121 and P4-0369. We are also grateful to Iva Hafner Bratkovič for contributing important knowledge on making and staining SDS-PAGE gels. This work was partially supported by the European Commission FP7 projects Prot-HiSPRA (grant number 282506) and HTP-GlycoMet (grant number 324400).
6. References
1.	R. Mayeux, Neurotherapeutics, 2004, 1, 182-188. http://dx.doi.org/10.1602/neurorx.L2.182
2.	N. C. Garbett, J. J. Miller, A. B. Jenson, J. B. Chaires, Biophys. J., 2008, 94, 1377-1383. http://dx.doi.org/10.1529/biophysj.107.119453
3.	P. Maurya, P. Meleady, P. Dowling, M. Clynes, Anticancer Res., 2007, 27, 1247-1256. http://ar.iiarjournals.org/content/27/3A/1247.long
4.	N. C. Garbett, M. L. Merchant, C. W. Helm, A. B. Jenson, J. B. Klein, J. B. Chaires, PLoS One, 2014, 9, e84710, 1-12. http://dx.doi.org/10.1371/journal.pone.0084710
5.	T. Čerk Petrič, P. Brne, B. Gabor, L. Govednik, M. Barut, A. Strancar, L. Zupančič Kralj, J. Pharm. Biomed. Anal., 2007,
43, 243-249. http://dx.doi.Org/10.1016/j.jpba.2006.06.019
6.	C. Wu, J. Duan, T. Liu, R. D. Smith, W.-J. Qian, J. Chroma-togr. B Analyt. Technol. Biomed. Life Sci., 2016, 1021, 57-68. http://dx.doi.Org/10.1016/j.jchromb.2016.01.015
7.	U. Cernigoj, U. Vidic, B. Nemec, J. Gaspersic, J. Vidic, N. Lendero Krajnc, A. Strancar, A. Podgornik, J. Chromatogr.
A,	2016, 1464, 72-78.
http://dx.doi.org/10.1016Zj.chroma.2016.08.014
8.	N. C. Garbett, C. S. Mekmaysy, C. W. Helm, A. B. Jenson, J.
B.	Chaires, Exp. Mol. Pathol. 2009, 86, 186-191. http://dx.doi.org/10.1016/j.yexmp.2008.12.001
9.	C. M. Stoscheck, Methods in Enzymol., 1990, 182, 50-69. http://dx.doi.org/10.1016/0076-6879(90)82008-P
10.1. A. Tarasova, A. A. Lobas, U. Cernigoj, E. M. Solovyeva, B. Mahlberg, M. V. Ivanov, T. Panic-Jankovic, Z. Nagy, M. L. Pridatchenko, A. Pungor, B. Nemec, U. Vidic, J. Gaspersic, N. Lendero Krajnc, J. Vidic, M. V. Gorshkov, G. Mitulovic, Electrophoresis, 2016, 37, 2322-2327. http://dx.doi.org/10.1002/elps.201500489
11.	U. K. Laemmli, Nature, 1970, 227, 680-685. http://dx.doi.org/10.1038/227680a0
12.	M. Chevallet, S. Luche, T. Rabilloud, Nat. Protoc., 2006, 1, 1852-1858. http://dx.doi.org/10.1038/nprot.2006.288
13.	C. M. Olsen, H.-T. Lee, L. A. Marky, J. Phys. Chem. B, 2009, 113, 2587-2595. http://dx.doi.org/10.1021/jp806853n
14.	N. C. Garbett, M. L. Merchant, J. B. Chaires, J. B. Klein, Biochim. Biophys. Acta, 2013, 1830, 4675-4680. http://dx.doi.org/10.1016/j.bbagen.2013.05.007
15.	A. Michnik, Z. Drzazga, K. Michalik, A. Barczyk, I. Santu-ra, E. Sozariska, W. Pierzchala, J. Therm. Anal. Calorim., 2010,102, 57-60.
http://dx.doi.org/10.1007/s10973-009-0602-6
16.	L. Kikalishvili, M. Ramishvili, G. Nemsadze, T. Lezhava, P. Khorava, M. Gorgoshidze, M. Kiladze, J. Monaselidze, J. Therm. Anal. Calorim., 2015, 120, 501-505. http://dx.doi.org/10.1007/s10973-015-4426-2
17.	S. Todinova, S. Krumova, L. Gartcheva, C. Robeerst, S. G. Taneva, Anal. Chem., 2011, 83, 7992-7998. http://dx.doi.org/10.1021/ac202055m
18.	G. A. Pico, Int. J. Biol. Macromol., 1997, 20, 63-73. http://dx.doi.org/10.1016/S0141-8130C96j01153-1
19.	A. Kumar Shaw, S. Kumar Pal, J. Photoch. Photobio. B., 2008, 90, 69-77.
http://dx.doi.org/10.1016/j.jphotobiol.2007.11.003
20.	D. F. Keren: Protein Electrophoresis in Clinical Diagnosis, Hodder Arnold, London, Great Britain, 2003, pp. 63-108 and 151-168.
http://www.aun.edu.eg/molecular_biology/Protein% 20workshop/&%20Protein%20Ele ctrophoresis_clinical% 20diagnosis.pdf
21.	R. Thakur, A. Das, V. Sharma, C. Adhikari, K. S. Ghosh, A. Chakraborty, Phys. Chem. Chem. Phys., 2015, 17, 1693716946. http://dx.doi.org/10.1039/c4cp05734a
22.	F. Barcelo, J. J. Cerda, A. Gutierrez, T. Jimenez-Marco, M. A. Duran, A. Novo, T. Ros, A. Sampol, J. Portugal, PLoS ONE, 2015, 10, 1-15.
http://dx.doi.org/10.1371/journal.pone.0120316
Povzetek
Diferenčna dinamična kalorimetrija (DSC) nam nudi svojevrsten vpogled v lastnosti proteoma krvne plazme. Termogrami krvne plazme bolnih posameznikov so specifični in se razlikujejo med seboj, kakor tudi od krvne plazme zdravih posameznikov. Z DSC smo izmerili termograme krvne plazme posameznikov s kronično limfatično levkemijo, plazmocitomom in akutno mieloično levkemijo ter jih med seboj primerjali. Da bi pridobili dodatne informacije o termično inducirani denaturaciji plazemskih proteinov, smo uporabili imunoafinitetno kromatografijo. S kromatografsko kolono z imobiliziranimi anti-HSA protitelesi smo izvedli imunoekstrakcijo HSA in s tem povišali delež manj pogostih proteinov v krvni plazmi. To nam je omogočilo snemanje termogramov frakcij z različno proteinsko sestavo in s tem boljše razumevanje interakcij med proteini, ki sestavljajo krvno plazmo. Učinkovitost odstranitve HSA in sestavo frak-cionirane krvne plazme smo preverili z uporabo SDS-PAGE.